about
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of ageAge, Spatial, and Temporal Variations in Hospital Admissions with Malaria in Kilifi County, Kenya: A 25-Year Longitudinal Observational StudyA genome wide association study of Plasmodium falciparum susceptibility to 22 antimalarial drugs in KenyaA phase 3 trial of RTS,S/AS01 malaria vaccine in African infantsA phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in KenyaClearance of asymptomatic P. falciparum Infections Interacts with the number of clones to predict the risk of subsequent malaria in Kenyan childrenChanging Malaria Prevalence on the Kenyan Coast since 1974: Climate, Drugs and Vector ControlSerological evidence of discrete spatial clusters of Plasmodium falciparum parasitesCircumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malariaSafety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenEfficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data.Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialEffect of transmission intensity on hotspots and micro-epidemiology of malaria in sub-Saharan Africa.Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.Defining childhood severe falciparum malaria for intervention studiesHelminth infection and eosinophilia and the risk of Plasmodium falciparum malaria in 1- to 6-year-old children in a malaria endemic area.Interactions between age and ITN use determine the risk of febrile malaria in children.Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya.Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya.HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria.Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus AnkaraAssessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient carePlasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP).Estimating individual exposure to malaria using local prevalence of malaria infection in the field.Memory B cells are a more reliable archive for historical antimalarial responses than plasma antibodies in no-longer exposed children.Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsA combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01ELack of avidity maturation of merozoite antigen-specific antibodies with increasing exposure to Plasmodium falciparum amongst children and adults exposed to endemic malaria in Kenya.The ratio of monocytes to lymphocytes in peripheral blood correlates with increased susceptibility to clinical malaria in Kenyan childrenSafety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsThe relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection.Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injectionAvidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.Acute seizures attributable to falciparum malaria in an endemic area on the Kenyan coast.Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children.Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studiesThick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite densityEvaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
P50
Q24658073-E8E5620B-0B2E-4592-8503-657DD13F797CQ27306991-2496BC33-485D-4EE1-9FA2-0D533FA51FB2Q28031418-B1F568B8-2DD5-4B25-8597-09A0CCAD8640Q28278852-8C20B2EC-74CA-4BF1-9169-A8E6C58B7CD8Q28469062-19510F28-C041-4B7E-8D86-2AD1C38CF6B4Q28477259-EC9BD2FD-5D48-413A-A271-DF2F35F63D02Q28548617-D7069724-7296-4C68-856B-CDA24A36F844Q28743081-CDA443DE-68C8-4662-8B64-DBFDB013D48DQ28744170-0465EDBA-4BD6-4855-8D0A-9484923AAB14Q28744573-5A2E46D6-8170-42E7-A2D6-19E52D5CBC1CQ30596414-81BECC91-9FD4-495A-B56A-AE4489793B08Q30662529-48FF17CD-551B-43D3-9D69-44990C9AAB26Q30991737-0178AB2A-85E9-48E5-AEB1-E3C3D68B45D8Q32174317-0C6680EF-489E-4DC8-8557-2F93726C391FQ33294698-D9F3EB1B-0B2C-4169-B8B7-16762289D5B3Q33294896-4E0F0B41-792D-4A8A-835C-86B22ECC971BQ33319239-D6C5387B-CD23-420B-AAD2-CC5D78A8ACF1Q33520924-119DD904-88BE-4493-AB9C-085B3F89797BQ33631268-1139BF63-3804-4B54-81CE-D73BACC116E5Q33778747-725A9B31-4A1D-43CC-BEA6-74B55B5E0892Q33785634-EFC6A47B-F0DE-41B5-A94C-0F902AC01111Q33935092-CB43CBB2-9650-4F3E-A9F1-EE1107083851Q33981953-246063C4-26CB-431C-9935-2065647F0878Q34215916-B2A314B6-D1DC-4EC0-89B0-4CD87EF84C28Q34221250-25591209-858C-4381-9881-980DAF9F75A7Q34261333-64ABF834-E188-4B46-A385-8796DD11C66BQ34301461-AD67B7BB-4E88-423F-9453-E879303F0DF2Q34487139-EFEFCD69-24FF-441D-8528-E5E685DFE087Q34541330-44CF5BFA-9EB9-4477-B6A9-5E368BAA1808Q34541443-3B9BD96B-D737-4E03-AC4A-07D957C1797AQ34600408-FDA9C8A1-8B67-4636-8B99-9B955A46085DQ34634002-00C6C5D1-F8DB-45D3-9220-A407CC3A042AQ34684347-CF2FD15C-ED1E-4E6E-AAF3-91D662C89B37Q34687174-FDF5DE32-72C8-488F-813F-8EF25AE512CBQ34704130-E0E63B01-9E3C-42F0-ACB0-21995D3F6894Q34992158-822AAC3E-4216-4D68-8B01-49201D100FDEQ35016669-2A57864A-1C36-47C3-917E-B0BB196C7603Q35052801-79309EE0-4144-4FFB-B733-2FBB2DA27596Q35131085-20A9CAEF-79A4-4F93-AFCD-A5AE07BB7C33Q35163318-C6D2D0AA-5C7E-4AF4-810F-7533BA3DF58D
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Philip Bejon
@af
Philip Bejon
@an
Philip Bejon
@ast
Philip Bejon
@bar
Philip Bejon
@br
Philip Bejon
@ca
Philip Bejon
@co
Philip Bejon
@cs
Philip Bejon
@cy
Philip Bejon
@da
type
label
Philip Bejon
@af
Philip Bejon
@an
Philip Bejon
@ast
Philip Bejon
@bar
Philip Bejon
@br
Philip Bejon
@ca
Philip Bejon
@co
Philip Bejon
@cs
Philip Bejon
@cy
Philip Bejon
@da
prefLabel
Philip Bejon
@af
Philip Bejon
@an
Philip Bejon
@ast
Philip Bejon
@bar
Philip Bejon
@br
Philip Bejon
@ca
Philip Bejon
@co
Philip Bejon
@cs
Philip Bejon
@cy
Philip Bejon
@da
P106
P166
P21
P31
P496
0000-0002-2135-7549